A recent study published in Volume 13 of Oncoscience on February 6, 2026, examines the gastrointestinal side effects linked to targeted cancer therapies. The research, led by Muhammad Moseeb Ali Hashim and Kamran Zahoor from the University of Missouri-Columbia, investigates how drugs such as tyrosine kinase inhibitors, antibody–drug conjugates, and CAR-T cell therapies can affect the digestive system.
The authors reviewed clinical trials, FDA drug labels, national safety databases, and pathology reports. Their analysis found that these treatments can cause unique and sometimes severe injuries to the gastrointestinal tract. These adverse effects are often overlooked in clinical practice. The researchers suggest that increased awareness could lead to earlier diagnosis and better treatment decisions for patients.
Targeted therapies have changed the management of cancers like colorectal cancer, gastric cancer, liver cancer, and gastrointestinal stromal tumors by focusing on specific molecular targets rather than using traditional chemotherapy. Despite their precision, these drugs may still damage healthy digestive tissue. This makes monitoring for gastrointestinal toxicity increasingly important as more patients receive these treatments.
Different classes of targeted drugs produce different patterns of injury. Tyrosine kinase inhibitors may decrease blood vessel growth in the gut and result in symptoms such as diarrhea or abdominal pain; they can also cause bleeding or bowel perforation in rare cases. Antibody–drug conjugates might harm normal intestinal lining cells leading to nausea or colitis. CAR-T cell therapy has been associated with widespread immune-related inflammation affecting the digestive tract.
These side effects may mimic other conditions like infections or inflammatory bowel disease. Biopsy samples might show signs such as cell death or ulceration that could be misinterpreted if doctors are unaware of a patient’s treatment history. The authors emphasize collaboration among oncologists, gastroenterologists, and pathologists for accurate diagnosis.
The paper discusses how national safety systems like the FDA Adverse Event Reporting System track reported complications related to these therapies. By combining clinical data with pathology findings and regulatory information from sources such as this database (https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers), drug monitoring efforts can be improved nationwide.
"Looking forward, progress will depend on bridging critical research gaps particularly in real-world histopathology correlation, microbiome interactions, and predictive biomarkers of toxicity while embedding digital tools for patient-reported outcomes and pharmacovigilance," state the authors.
The study presents a framework for recognizing and managing digestive side effects from targeted cancer treatments by integrating clinical experience with pathological analysis and regulatory oversight. As precision oncology develops further, coordinated care remains key to ensuring both effectiveness and safety for patients receiving these therapies.
